HER2+ Breast Cancer SK-BR-3 Cells Available
At Cytion, we are pleased to offer high-quality SK-BR-3 cells, a vital research tool for scientists investigating HER2-positive breast cancer. These cells represent one of the most extensively characterized and widely used models for studying aggressive breast cancer subtypes, making them indispensable for oncological research, drug development, and therapeutic testing. Our SK-BR-3 cell line maintains the critical characteristics that have made it a gold standard in breast cancer cell lines research for decades.
Key Takeaways
| Characteristic | Details |
|---|---|
| Cell Line | SK-BR-3 (Product #300333) |
| Cancer Type | HER2-positive breast adenocarcinoma |
| Key Features | High HER2/neu expression, estrogen receptor negative |
| Research Applications | Drug screening, HER2-targeted therapy development, cancer biology studies |
| Quality Assurance | Authenticated, mycoplasma-free, comprehensive characterization |
| Clinical Relevance | Models aggressive breast cancer subtype affecting 20-25% of patients |
Understanding SK-BR-3: A Premier HER2-Positive Research Model
The SK-BR-3 cells available from Cytion represent one of the most valuable and extensively validated models for HER2-positive breast cancer research. Originally derived from a pleural effusion of a 43-year-old Caucasian female with breast adenocarcinoma, these cells have become the gold standard for investigating aggressive breast cancer biology. Our SK-BR-3 cell line exhibits robust HER2/neu overexpression, making it an ideal model for studying targeted therapies, drug resistance mechanisms, and cellular signaling pathways. Researchers worldwide rely on these cells for developing breakthrough treatments, and at Cytion, we ensure each vial meets the highest quality standards through rigorous cell line authentication and comprehensive mycoplasma testing protocols.
HER2-Positive Breast Adenocarcinoma: Clinical Significance and Research Impact
HER2-positive breast adenocarcinoma represents approximately 20-25% of all breast cancer cases and is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2/neu) protein. This aggressive cancer subtype historically carried a poor prognosis due to its rapid growth and high metastatic potential, making it a critical focus for targeted therapeutic development. The SK-BR-3 cells perfectly recapitulate the molecular characteristics of this challenging cancer type, providing researchers with an authentic in vitro model for studying HER2-driven oncogenic pathways. These cells are particularly valuable for evaluating HER2-targeted therapies such as trastuzumab, pertuzumab, and newer antibody-drug conjugates. Our comprehensive collection of breast cancer cell lines includes various molecular subtypes, but SK-BR-3 remains uniquely important due to its consistent HER2 amplification and its role in validating countless therapeutic breakthroughs that have transformed patient outcomes in the clinic.
Molecular Characteristics: HER2 Overexpression and Hormone Receptor Status
The defining molecular features of SK-BR-3 cells include exceptionally high HER2/neu expression levels combined with estrogen receptor (ER) and progesterone receptor (PR) negativity, classifying them as a HER2-enriched subtype. This unique molecular profile makes SK-BR-3 cells distinct from hormone-positive models like MCF-7 cells or triple-negative breast cancer lines such as MDA-MB-231 cells. The high HER2 expression in SK-BR-3 cells results from gene amplification, leading to approximately 2 million HER2 receptors per cell compared to 20,000-50,000 in normal cells. This overexpression drives constitutive growth signaling through PI3K/AKT and MAPK pathways, making these cells highly proliferative and resistant to apoptosis. Researchers can confidently use our authenticated SK-BR-3 cells to investigate HER2-specific mechanisms, validate biomarker expression, and test therapeutic interventions, knowing that each batch undergoes rigorous quality control including comprehensive cell line authentication to ensure genetic integrity and phenotypic consistency.
Research Applications: From Drug Discovery to Therapeutic Development
The versatility of SK-BR-3 cells makes them indispensable for multiple research applications, particularly in drug screening and HER2-targeted therapy development. These cells serve as primary screening models for evaluating novel therapeutic compounds, antibody-drug conjugates, and combination therapies targeting HER2-positive cancers. Researchers utilize SK-BR-3 cells extensively in cancer biology studies to investigate mechanisms of drug resistance, metastasis, and cellular responses to targeted interventions. The cells' consistent HER2 overexpression makes them ideal for validating new biomarkers and understanding HER2-driven signaling cascades. When combined with other models from our extensive breast cancer cell lines collection, such as MCF10A cells for normal breast epithelial comparisons or BT-20 cells for triple-negative studies, SK-BR-3 cells enable comprehensive comparative analyses. To ensure optimal experimental outcomes, we recommend pairing these cells with our specialized culture media and maintaining them using our proven Freeze Medium CM-1 for long-term storage and viability preservation.
Quality Assurance: Rigorous Standards for Research Excellence
At Cytion, our commitment to research excellence is demonstrated through comprehensive quality assurance protocols applied to every batch of SK-BR-3 cells we supply. Each cell line undergoes rigorous cell line authentication using STR (Short Tandem Repeat) profiling to confirm genetic identity and prevent cross-contamination, ensuring researchers receive genuine SK-BR-3 cells with verified provenance. Our mandatory mycoplasma testing protocols guarantee that all cells are free from this common laboratory contaminant that can compromise experimental results and cellular behavior. Beyond basic authentication, we provide comprehensive characterization including morphological assessment, growth kinetics evaluation, and marker expression validation to confirm HER2 overexpression levels. This multi-layered quality approach extends to our professional cell banking services, where we maintain optimal storage conditions and detailed documentation for each cell line. Every SK-BR-3 cell shipment includes a detailed Certificate of Analysis documenting all quality control results, giving researchers the confidence that their experimental foundation is built on authenticated, contaminant-free, and thoroughly characterized cells.
Clinical Relevance: Bridging Laboratory Research to Patient Care
The clinical significance of SK-BR-3 cells extends far beyond the laboratory, as they faithfully model an aggressive breast cancer subtype that affects approximately 20-25% of breast cancer patients worldwide. This translational relevance makes SK-BR-3 cells invaluable for preclinical studies that directly inform clinical decision-making and therapeutic development strategies. The breakthrough success of HER2-targeted therapies like trastuzumab (Herceptin), pertuzumab (Perjeta), and T-DM1 (Kadcyla) can be traced back to fundamental research conducted using SK-BR-3 cells, demonstrating their predictive value for clinical outcomes. Researchers utilizing our authenticated SK-BR-3 cells contribute to ongoing efforts to overcome therapeutic resistance, identify novel combination strategies, and develop next-generation HER2-targeted agents. When combined with other clinically relevant models from our human cells collection, such as HUVEC, single donor for vascular studies or Human Mesenchymal Stem Cells - Bone Marrow (HMSC-BM) for microenvironment investigations, SK-BR-3 cells enable comprehensive cancer research that translates laboratory discoveries into life-saving treatments for patients battling HER2-positive breast cancer.